Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa to reduce top-up transfusions in neonates with alloimmune hemolytic disease after intrauterine transfusion
2017-000583-15Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2017
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of darbepoetin alfa in Erythroblastosis fetalis (HDFN) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Number of top-up transfusions per infant up to 3 months of life. Started Jun 2017; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on 2017-000583-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000583-15.